Disulfiram

From Glioblastoma Treatments
Revision as of 08:32, 19 March 2024 by Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=Disulfiram (Antabuse) |FDA_approval=Yes (for preventing alcohol consumption) |used_for=Exploratory treatment for GBM in combination with temozolomide and potentially copper gluconate |clinical_trial_phase=Phase I pharmacodynamics trial at Washington University, ongoing research |common_side_effects=At higher doses: delirium and peripheral motor neuropathy; minimal toxicity when alcohol is not consumed |OS_without=Not specified |OS_with=Early re...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name Disulfiram (Antabuse)
FDA Approval Yes (for preventing alcohol consumption)
Used for Exploratory treatment for GBM in combination with temozolomide and potentially copper gluconate
Clinical Trial Phase Phase I pharmacodynamics trial at Washington University, ongoing research
Clinical Trial Explanation Not specified
Common Side Effects At higher doses: delirium and peripheral motor neuropathy; minimal toxicity when alcohol is not consumed
OS without Not specified
OS with Early results suggest potential efficacy in enhancing chemotherapy response; ongoing trials
PFS without Not specified
PFS with Initial results indicate a need for dosage optimization to balance efficacy and side effects
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified

Notes: Disulfiram, a drug traditionally used to prevent alcohol consumption, shows promise in GBM treatment through mechanisms such as blocking glycoprotein pumps and inhibiting MGMT enzyme and metalloproteinase activity. It's believed to inhibit the growth of cancer stem cells, a major source of treatment failures. Its anticancer effects may be potentiated by concurrent use of copper gluconate. Current trials are investigating optimal dosing and combination strategies to maximize therapeutic outcomes.


From Ben Williams Book: Not specified

Loading comments...